Abstract
Background/objectives: Despite various reports from different countries demonstrating the safety and efficacy of elexacaftor-tezacaftor-ivacaftor (ETI) therapy in people with CF (PwCF) carrying at least one copy of F508del-CFTR, it is still not available for PwCF by the Brazilian Public Healthcare System. Here, we reported the clinical outcomes of 22 Brazilians with CF who earned the right to receive ETI therapy through court rulings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
